• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

GSK-2126458

Product ID G7342
Cas No. 1086062-66-9
Purity ≥99%
Product Unit SizeCostQuantityStock
1 mg $61.50 In stock
5 mg $116.00 In stock
25 mg $354.40 In stock
Bulk Quote
Add to Wishlist

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

GSK-2126458 is an ATP-competitive PI3K and mTOR inhibitor somewhat specific for the p110α isoform of PI3K. This compound exhibits anticancer chemotherapeutic activity, inhibiting growth in cellular models. GSK-2126458 is currently in clinical trials for treatment of a variety of solid tumor cancers.

Product Info

Cas No.

1086062-66-9

Purity

≥99%

Formula

C25H17F2N5O3S

Formula Wt.

505.50

Chemical Name

2,4-difluoro-N-[2-methoxy-5-(4-pyridazin-4-ylquinolin-6-yl)pyridin-3-yl] benzenesulfonamide

IUPAC Name

2, 4-difluoro-N-[2-methoxy-5-(4-pyridazin-4-ylquinolin-6-yl)pyridin-3-yl] benzenesulfonamide

Synonym

GSK458, Omipalisib

Solubility

DMSO 100 mg/mL (197.82 mM) Water Insoluble Ethanol Insoluble

Appearance

light yellow powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

G7342 MSDS PDF

Info Sheet

G7342 Info Sheet PDF

Brochures

PI3K-Akt-mTORC Pathway Booklet

References

Greger JG, Eastman SD, Zhang V, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 2012 Apr;11(4):909-20. PMID: 22389471.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only